MARX Biotech Co., Ltd. (TPEX:7731)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Retail - Drugs	289.93M	110.64M
Retail - Drugs Growth	162.04%	-
Total	289.93M	110.64M
Total Growth	162.04%	-

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Taiwan	284.62M	104.45M
Taiwan Growth	172.49%	-
China	3.30M	4.39M
China Growth	-24.70%	-
Singapore and Malaysia	2.00M	1.80M
Singapore and Malaysia Growth	10.92%	-
Total	289.93M	110.64M
Total Growth	162.04%	-

Source: S&P Global Market Intelligence.